Impact of antagonist peptides and chelators on the diagnostic performance of PET/CT using gallium-68-labeled somatostatin receptor antagonists  

作　　者：Haiqun Xing Wenjia Zhu Yuejuan Cheng Qiao Yang Ru Jia Hong Zhao Chunmei Bai Li Huo Wenming Wu 

机构地区：[1]Nuclear Medicine Department,State Key Laboratory of Complex Severe and Rare Diseases,Center for Rare Diseases Research,Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing,China [2]Department of Oncology,Peking Union Medical College Hospital,Beijing,China [3]Department of Gastrointestinal Oncology,the fifth Medical Center,General Hospital of PLA,Beijing,China [4]Department of Hepatobiliary Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [5]Department of General Surgery,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing,China

出　　处：《Journal of Pancreatology》2023年第1期28-33,共6页胰腺病学杂志（英文）

基　　金：National Natural Science Foundation of China(No. 82071967);CAMS initiative for innovative medicine(No. CAMS-2018-I2M-3-001);National Key Research and Development Program of China(No. 2016YFC0901500);Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China(No. 2016ZX310174-4)。

摘　　要：Objective: Different SSTR2 antagonists have been developed. This study aims to evaluate the impact of different peptides and chelators on the diagnostic performance of SSTR2 antagonists in well-differentiated NETs.Methods: In this prospective study, participants were equally randomized into 2 arms: arm A, participants would undergo a whole-body^(68)Ga-NODAGA-LM3 PET/CT scan on the first day and^(68)Ga-DOTA-LM3 PET/CT scan on the second day;arm B, participants would undergo a whole-body^(68)Ga-NODAGA-LM3 PET/CT scan on the first day and^(68)Ga-NODAGA-JR11 PET/CT scan on the second day. Biodistribution in normal organs, lesion detection ability, and tumor uptakes were compared within each arm.Results: A total of 40 participants (age, 49.5 ± 13.4, 21 men), 20 in each arm, were recruited in the study. In arm A,^(68)Ga-DOTA-LM3 showed lower background. However, the lesion detection ability (overall lesion detected, 445 vs 548;P = .005) and the lesion uptake (overall lesions SUVmax, 19.8 ± 17.2 vs 35.3 ± 28.8;P < .001) was significantly lower than those of^(68)Ga-NODAGA-LM3. In arm B, both^(68)Ga-NODAGA-LM3 and^(68)Ga-NODAGA-JR11 showed similar biodistribution and lesion uptake (SUVmax, 28.5 ± 23.8 vs 25.0 ± 20.0;P < .001) despite minor differences. The lesion detection ability was the same between these 2 tracers (overall lesion detected, 503 vs 503).Conclusions: The diagnostic performance of SSTR2 antagonists was sensitive to chelators. Both^(68)Ga-NODAGA-LM3 and^(68)Ga-NODAGA-JR11 outperformed^(68)Ga-DOTA-LM3 with higher lesion uptake and detection ability, of which^(68)Ga-NODAGA-LM3 had marginally but significantly higher lesion uptake.

关 键 词：-DOTA-LM3 68Ga-NODAGA-JR11 68Ga-NODAGA-LM3 Neuroendocrine tumor Somatostatin receptor antagonist 

分 类 号：R730[医药卫生—肿瘤]